Publications - IR Sant Pau

Search

11/01/2022 Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Wieduwilt, MJ, Metheny, L, Zhang, MJ, Wang, HL, Estrada-Merly, N, Marks, DI, Al-Homsi, AS, Muffly, L, Chao, N, Rizzieri, D, Gale, RP, Gadalla, SM, Cairo, M, Mussetti, A, Gore, S, Bhatt, VR, Patel, SS, Michelis, FV, Inamoto, Y, Badawy, SM, Copelan, E, Palmisiano, N, Kharfan-Dabaja, MA, Lazarus, HM, Ganguly, S, Bredeson, C, Perez, MAD, Cassaday, R, Savani, BN, Ballen, K, Martino, R, Wirk, B, Bacher, U, Aljurf, M, Bashey, A, Murthy, HS, Yared, JA, Aldoss, I, Farhadfar, N, Liu, HT, Abdel-Azim, H, Waller, EK, Solh, M, Seftel, MD, van der Poel, M, Grunwald, MR, Liesveld, JL, Kamble, RT, McGuirk, J, Munker, R, Cahn, JY, Lee, JW, Freytes, CO, Krem, MM, Winestone, LE, Gergis, U, Nathan, S, Olsson, RF, Verdonck, LF, Sharma, A, Ringden, O, Friend, BD, Cerny, J, Choe, H, Chhabra, S, Nishihori, T, Seo, S, George, B, Baxter-Lowe, LA, Hildebrandt, GC, de Lima, M, Litzow, M, Kebriaei, P, Hourigan, CS, Abid, MB, Weisdorf, DJ, Saber, W. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances. 2022; 6(1)DOI:10.1182/bloodadvances.2021004916. PMID:34547770. IF:7.500(Q1/2D).

01/01/2022 Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT

Mikulska, M, Knelange, N, Nicolini, LA, Tridello, G, Santarone, S, Di Bartolomeo, P, de la Camara, R, Cuellar, C, Velardi, A, Perruccio, K, Ljungman, P, Zaucha, J, Piekarska, A, Basak, G, Karakulska-Prystupiuk, E, Angelucci, E, Ciceri, F, Lupo-Stanghellini, MT, Fouillard, L, Garcia-Cadenas, I, Menconi, M, Blau, IW, Nassi, L, Cesaro, S, Styczynski, J. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT. JOURNAL OF INFECTION. 2022; 84(1)DOI:10.1016/j.jinf.2021.10.024. PMID:34757138. IF:28.200(Q1/1D).

01/01/2022 Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials

Serna, N, Falgas, A, Garcia-Leon, A, Unzueta, U, Nunez, Y, Sanchez-Chardi, A, Martinez-Torro, C, Mangues, R, Vazquez, E, Casanova, I, Villaverde, A. Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials. Pharmaceutics. 2022; 14(1)DOI:10.3390/pharmaceutics14010192. PMID:35057088. IF:5.400(Q1/2D).

01/12/2021 Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

Wierda, WG, Allan, JN, Siddiqi, T, Kipps, TJ, Opat, S, Tedeschi, A, Badoux, XC, Kuss, BJ, Jackson, S, Moreno, C, Jacobs, R, Pagel, JM, Flinn, I, Pak, Y, Zhou, C, Szafer-Glusman, E, Ninomoto, J, Dean, JP, James, DF, Ghia, P, Tam, CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(34)DOI:10.1200/JCO.21.00807. PMID:34618601. IF:50.739(Q1/1D).

23/11/2021 Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

Dickinson, M, Briones, J, Herrera, AF, Gonzalez-Barca, E, Ghosh, N, Cordoba, R, Rutherford, SC, Bournazou, E, Labriola-Tompkins, E, Franjkovic, I, Chesne, E, Brouwer-Visser, J, Lechner, K, Brennan, B, Nuesch, E, DeMario, M, Ruttinger, D, Kornacker, M, Hutchings, M. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Advances. 2021; 5(22)DOI:10.1182/bloodadvances.2021004619. PMID:34581757. IF:7.642(Q1/3D).

01/01/2023 High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion

Caballero A.C., Escribà-Garcia L., Pujol-Fernández P., Escudero-López E., Ujaldón-Miró C., Montserrat-Torres R., Sierra J., Alvarez-Fernández C., Briones J.. High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion. CANCER GENE THERAPY. 2023; 30(1)DOI:10.1038/s41417-022-00518-6. PMID:36031661. IF:4.800(Q1/2D).

01/01/2023 Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope

Del Principe, MI, Seidel, D, Criscuolo, M, Dargenio, M, Racil, Z, Piedimonte, M, Marchesi, F, Nadali, G, Koehler, P, Fracchiolla, N, Cattaneo, C, Klimko, N, Spolzino, A, Karapinar, DY, Demiraslan, H, Duarte, RF, Demeter, J, Stanzani, M, Melillo, LMA, Basilico, CM, Cesaro, S, Paterno, G, Califano, C, Delia, M, Buzzatti, E, Busca, A, Cornely, OA, Pagano, L, Alakel, N, Arsenijevi'c, VA, Camus, V, Falces-Romero, I, Itzhak, L, Kouba, M, Martino, R, Sedlacek, P, Weinbergerova, B. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope. MYCOSES. 2023; 66(1)DOI:10.1111/myc.13524. PMID:36064299. IF:4.100(Q1/2D).

01/12/2022 5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics

Diaz-Santa, J, Rodriguez-Romanos, R, Coll, R, Osca, G, Pratcorona, M, Gonzalez-Bartulos, M, Garrido, A, Angona, A, Talarn, C, Tormo, M, Arnan, M, Vives, S, Salamero, O, Tuset, E, Lloveras, N, Diez, I, Zamora, L, Bargay, J, Sampol, A, Cruz, D, Vila, J, Sitges, M, Garcia, A, Vall-Llovera, F, Esteve, J, Sierra, J, Gallardo, D. 5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics. EUROPEAN JOURNAL OF HAEMATOLOGY. 2022; 109(6)DOI:10.1111/ejh.13862. PMID:36063368. IF:3.100(Q3/6D).

01/12/2022 Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications

Baptista, MJ, Tapia, G, Munoz-Marmol, AM, Muncunill, J, Garcia, O, Montoto, S, Gribben, JG, Calaminici, M, Martinez, A, Veloza, L, Martinez-Trillos, A, Aldamiz, T, Menarguez, J, Terol, MJ, Ferrandez, A, Alcoceba, M, Briones, J, Gonzalez-Barca, E, Climent, F, Muntanola, A, Moraleda, JM, Provencio, M, Abrisqueta, P, Abella, E, Colomo, L, Garcia-Ballesteros, C, Garcia-Caro, M, Sancho, JM, Ribera, JM, Mate, JL, Navarro, JT. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. HISTOPATHOLOGY. 2022; 81(6)DOI:10.1111/his.14798. PMID:36109172. IF:6.400(Q1/2D).

01/12/2022 mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients

Albiol, N, Barata, A, Aso, O, Gomez-Perez, L, Triquell, M, Roch, N, Lazaro, E, Esquirol, A, Gonzalez, I, Lopez-Contreras, J, Sierra, J, Martino, R, Garcia-Cadenas, I. mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients. SUPPORTIVE CARE IN CANCER. 2022; 30(12)DOI:10.1007/s00520-022-07376-w. PMID:36169731. IF:3.100(Q1/3D).

01/11/2022 Optimising the management of patients with multiple myeloma in Spain: A measurement of the social return on investment

Merino, M, Ivanova, Y, Maravilla-Herrera, P, Barragan, B, Sierra, J, Penuelas-Saiz, A, Hidalgo-Vega, A. Optimising the management of patients with multiple myeloma in Spain: A measurement of the social return on investment. EUROPEAN JOURNAL OF CANCER CARE. 2022; 31(6)DOI:10.1111/ecc.13706. PMID:36177961. IF:2.100(Q2/4D).

01/10/2022 Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Nagler, A, Labopin, M, Cornelissen, JJ, Forcade, E, Chevallier, P, Fegueux, N, Sierra, J, Desmier, D, Labussiere-Wallet, H, Byrne, JL, Loschi, M, Blaise, D, Baron, F, Ruggeri, A, Mohty, M. Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPLANTATION. 2022; 57(10)DOI:10.1038/s41409-022-01742-2. PMID:35773347. IF:4.800(Q1/2D).

01/09/2022 Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients

Pinana, JL, Rodriguez-Belenguer, P, Caballero, D, Martino, R, Lopez-Corral, L, Terol, MJ, Vazquez, L, Calabuig, M, Sanz-Linares, G, Marin-Jimenez, F, Alonso, C, Montoro, J, Ferrer, E, Facal, A, Pascual, MJ, Rodriguez-Fernandez, A, Olave, MT, Cascales-Hernandez, A, Gago, B, Hernandez-Rivas, JA, Villalon, L, Corona, M, Roldan-Perez, A, Ribes-Amoros, J, Gonzalez-Santillana, C, Garcia-Sanz, R, Navarro, D, Serrano-Lopez, AJ, Cedillo, A, Soria-Olivas, E, Sureda, A, Solano, C. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. ANNALS OF HEMATOLOGY. 2022; 101(9)DOI:10.1007/s00277-022-04906-8. PMID:35780254. IF:3.500(Q2/5D).

01/08/2022 Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan

Guijarro, F, Bataller, A, Diaz-Beya, M, Garrido, A, Coll-Ferra, C, Vives, S, Salamero, O, Valcarcel, D, Tormo, M, Arnan, M, Sampol, A, Castano-Diez, S, Martinez, C, Suarez-Lledo, M, Fernandez-Aviles, F, Hernandez-Boluda, JC, Ribera, JM, Rovira, M, Brunet, S, Sierra, J, Esteve, J. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. BONE MARROW TRANSPLANTATION. 2022; 57(8)DOI:10.1038/s41409-022-01703-9. PMID:35643942. IF:4.800(Q1/2D).

01/08/2022 Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas

Moreno, DF, Clapes, V, Soler, JA, Gonzalez-Montes, Y, Gironella, M, Motllo, C, Granell, M, Abella, E, Garcia-Pintos, M, Garcia-Guinon, A, Cabezudo, E, Blade, J, Rosinol, L. Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas. Clinical Lymphoma Myeloma & Leukemia. 2022; 22(8)DOI:10.1016/j.clml.2022.04.014. PMID:35610120. IF:2.700(Q3/7D).

01/08/2022 TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype

Ramos-Campoy, S, Puiggros, A, Kamaso, J, Bea, S, Bougeon, S, Larrayoz, MJ, Costa, D, Parker, H, Rigolin, GM, Blanco, ML, Collado, R, Ancin, I, Salgado, R, Moro-Garcia, MA, Baumann, T, Gimeno, E, Moreno, C, Salido, M, Calvo, X, Calasanz, MJ, Cuneo, A, Nguyen-Khac, F, Oscier, D, Haferlach, C, Strefford, JC, Schoumans, J, Espinet, B. TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. Cancers. 2022; 14(15)DOI:10.3390/cancers14153715. PMID:35954380. IF:5.200(Q2/3D).

06/07/2022 CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure

Caballero, AC, Escriba-Garcia, L, Alvarez-Fernandez, C, Briones, J. CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure. Frontiers in Immunology. 2022; 13DOI:10.3389/fimmu.2022.904497. PMID:35874685. IF:7.300(Q1/3D).

09/06/2022 Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Perl, AE, Larson, RA, Podoltsev, NA, Strickland, S, Wang, ES, Atallah, E, Schiller, GJ, Martinelli, G, Neubauer, A, Sierra, J, Montesinos, P, Recher, C, Yoon, SS, Hosono, N, Onozawa, M, Chiba, S, Kim, HJ, Hasabou, N, Lu, QY, Tiu, R, Levis, MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. BLOOD. 2022; 139(23)DOI:10.1182/blood.2021011583. PMID:35081255. IF:20.300(Q1/1D).

02/06/2022 Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Tam, CS, Allan, JN, Siddiqi, T, Kipps, TJ, Jacobs, R, Opat, S, Barr, PM, Tedeschi, A, Trentin, L, Bannerji, R, Jackson, S, Kuss, BJ, Moreno, C, Szafer-Glusman, E, Russell, K, Zhou, C, Ninomoto, J, Dean, JP, Wierda, WG, Ghia, P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. BLOOD. 2022; 139(22)DOI:10.1182/blood.2021014488. PMID:35196370. IF:20.300(Q1/1D).

01/06/2022 The EHA Research Roadmap: Malignant Lymphoid Diseases

Dreyling, M, Andre, M, Gokbuget, N, Tilly, H, Jerkeman, M, Gribben, J, Ferreri, A, Morel, P, Stilgenbauer, S, Fox, C, Ribera, JM, Zweegman, S, Aurer, I, Bodor, C, Burkhardt, B, Buske, C, Caballero, MD, Campo, E, Chapuy, B, Davies, A, de Leval, L, Doorduijn, J, Federico, M, Gaulard, P, Gay, F, Ghia, P, Gronbaek, K, Goldschmidt, H, Kersten, MJ, Kiesewetter, B, Landman-Parker, J, Le Gouill, S, Lenz, G, Leppa, S, Lopez-Guillermo, A, Macintyre, E, Mantega, MVM, Moreau, P, Moreno, C, Nadel, B, Okosun, J, Owen, R, Pospisilova, S, Pott, C, Robak, T, Spina, M, Stamatopoulos, K, Stary, J, Tarte, K, Tedeschi, A, Thieblemont, C, Trappe, RU, Trumper, LH, Salles, G. The EHA Research Roadmap: Malignant Lymphoid Diseases. Hemasphere. 2022; 6(6)DOI:10.1097/HS9.0000000000000726. PMID:35620592. IF:6.600(Q1/3D).

01/06/2022 Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

Waszczuk-Gajda, A, Penack, O, Sbianchi, G, Koster, L, Blaise, D, Remenyi, P, Russell, N, Ljungman, P, Trneny, M, Mayer, J, Iacobelli, S, Kobbe, G, Scheid, C, Apperley, J, Touzeau, C, Lenhoff, S, Jantunen, E, Anagnostopoulos, A, Paris, L, Browne, P, Thieblemont, C, Schaap, N, Sierra, J, Yakoub-Agha, I, Garderet, L, Styczynski, J, Schoemans, H, Moiseev, I, Duarte, RF, Peric, Z, Montoto, S, van Biezen, A, Mikulska, M, Aljurf, M, Ruutu, T, Kroger, N, Morris, C, Koenecke, C, Schoenland, S, Basak, GW. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. Journal of Clinical Medicine. 2022; 11(12)DOI:10.3390/jcm11123541. PMID:35743620. IF:3.900(Q2/4D).

07/05/2022 SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

Pinana, JL, Lopez-Corral, L, Martino, R, Vazquez, L, Perez, A, Martin-Martin, G, Gago, B, Sanz-Linares, G, Sanchez-Salinas, A, Villalon, L, Conesa-Garcia, V, Olave, MT, Corona, M, Marcos-Corrales, S, Tormo, M, Hernandez-Rivas, JA, Montoro, J, Rodriguez-Fernandez, A, Risco-Galvez, I, Rodriguez-Belenguer, P, Hernandez-Boluda, JC, Garcia-Cadenas, I, Ruiz-Garcia, M, Munoz-Bellido, JL, Solano, C, Cedillo, A, Sureda, A, Navarro, D. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Journal of Hematology & Oncology. 2022; 15(1)DOI:10.1186/s13045-022-01275-7. PMID:35526045. IF:28.500(Q1/1D).

01/05/2022 Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis

Garcia-Fortes, M, Hernandez-Boluda, JC, Alvarez-Larran, A, Raya, JM, Angona, A, Estrada, N, Fox, L, Cuevas, B, Garcia-Hernandez, MC, Gomez-Casares, MT, Ferrer-Marin, F, Saavedra, S, Cervantes, F, Garcia-Delgado, R. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers. 2022; 14(9)DOI:10.3390/cancers14092331. PMID:35565461. IF:5.200(Q2/3D).

01/05/2022 Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers

Arranz, MJ, Salazar, J, Bote, V, Artigas-Baleri, A, Serra-LLovich, A, Trivino, E, Roige, J, Lombardia, C, Cancino, M, Hernandez, M, Cendros, M, Duran-Tauleria, E, Maraver, N, Hervas, A. Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers. Pharmaceutics. 2022; 14(5)DOI:10.3390/pharmaceutics14050999. PMID:35631585. IF:5.400(Q1/2D).

01/05/2022 Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

Reinoso-Segura, M, Caballero-Velazquez, T, Herrera, P, Patriarca, F, Fanin, R, Bruno, B, Einsele, H, Nahi, H, Granell, M, Lopez-Corral, L, Reguera, JL, Garcia-Cadenas, I, Gahrton, G, Perez-Simon, JA. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. Transplantation And Cellular Therapy. 2022; 28(5)DOI:10.1016/j.jtct.2022.01.026. PMID:35131486. IF:3.200(Q2/5D).

25/04/2022 Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group

Orgueira, AM, Perez, MSG, Arias, JD, Rosinol, L, Oriol, A, Teruel, AI, Lopez, JM, Palomera, L, Granell, M, Blanchard, MJ, de la Rubia, J, de la Guia, AL, Rios, R, Sureda, A, Hernandez, MT, Bengoechea, E, Calasanz, MJ, Gutierrez, N, Martin, ML, Blade, J, Lahuerta, JJ, San Miguel, J, Mateos, MV. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. Blood Cancer Journal. 2022; 12(4)DOI:10.1038/s41408-022-00647-z. PMID:35468898. IF:12.800(Q1/1D).

19/04/2022 A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

Encinas, C, Hernandez-Rivas, JA, Oriol, A, Rosinol, L, Blanchard, MJ, Bellon, JM, Garcia-Sanz, R, de la Rubia, J, de la Guia, AL, Jimenez-Ubieto, A, Jarque, I, Inigo, B, Dourdil, V, de Arriba, F, Perez-Avila, CC, Gonzalez, Y, Hernandez, MT, Bargay, J, Granell, M, Rodriguez-Otero, P, Silvent, M, Cabrera, C, Rios, R, Alegre, A, Gironella, M, Gonzalez, MS, Sureda, A, Sampol, A, Ocio, EM, Krsnik, I, Garcia, A, Garcia-Mateo, A, Soler, JA, Martin, J, Arguinano, JM, Mateos, MV, Blade, J, San-Miguel, JF, Lahuerta, JJ, Martinez-Lopez, J. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer Journal. 2022; 12(4)DOI:10.1038/s41408-022-00652-2. PMID:35440057. IF:12.800(Q1/1D).

01/03/2022 Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients

Ramos-Campoy, S, Puiggros, A, Bea, S, Bougeon, S, Larrayoz, MJ, Costa, D, Parker, H, Rigolin, GM, Ortega, M, Blanco, ML, Collado, R, Salgado, R, Baumann, T, Gimeno, E, Moreno, C, Bosch, F, Calvo, X, Calasanz, MJ, Cuneo, A, Strefford, JC, Nguyen-Khac, F, Oscier, D, Haferlach, C, Schoumans, J, Espinet, B. Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. HAEMATOLOGICA. 2022; 107(3)DOI:10.3324/haematol.2020.274456. PMID:33691382. IF:10.100(Q1/2D).

01/01/2022 Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges

Redondo, S, Esquirol, A, Novelli, S, Caballero, AC, Garrido, A, Onate, G, Lopez, J, Moreno, C, Saavedra, SD, Granell, M, Briones, J, Sierra, J, Martino, R, Garcia-Cadenas, I. Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. Transplantation And Cellular Therapy. 2022; 28(1)DOI:10.1016/j.jtct.2021.10.015. PMID:34757054. IF:3.200(Q2/5D).

01/12/2024 Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation

Redondo, S, Garcia-Cadenas, I, Esquirol, A, Portos, JM, Iranzo, E, Arguello-Tomas, M, Saavedra, S, Oñate, G, Caballero, AC, Garrido, A, López, J, Muntañola, A, Paviglianiti, A, Miqueleiz, S, Sierra, J, Briones, J, Martino, R. Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation. EUROPEAN JOURNAL OF HAEMATOLOGY. 2024; 113(6)DOI:10.1111/ejh.14294. PMID:39155459. IF:2.300(Q2/5D).

01/10/2024 Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil

Esquirol, A, Pascual, MJ, Montoro, J, Piñana, JL, Ferrà, C, Herruzo, B, Garcia-Cadenas, I, Balaguer, A, Perez, A, Huguet, M, Redondo, S, Villalba, M, Hernandez-Boluda, JC, Chorao, P, Hernani, R, Sanz, J, Solano, C, Sierra, J, Martino, R. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil. Transplantation And Cellular Therapy. 2024; 30(10)DOI:10.1016/j.jtct.2024.07.027. PMID:39116938. IF:4.400(Q1/1D).

14/09/2024 Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC

Salas, MQ, Cascos, E, López-García, A, Pérez-López, E, Baile-González, M, López-Corral, L, Cascón, MJP, Luque, M, Esquirol, A, Fernando, IH, Ormtegi, IO, Marin, AJS, Peña-Muñóz, F, Fernández-Luis, S, Domínguez-García, JJ, Fernández, SV, Girón, MFD, Pinedo, LG, González-Rodríguez, AP, Torrado, T, García, L, Filaferro, S, Cedillo, A, Basalobre, P, Ortí, G, Chacón, MJ. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC. BONE MARROW TRANSPLANTATION. 2024; 59(12)DOI:10.1038/s41409-024-02414-z. PMID:39277653. IF:5.200(Q1/1D).

31/08/2024 Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Piñana, JL, Giménez, E, Vázquez, L, Marcos, MA, Guerreiro, M, Duarte, R, Pérez, A, de Miguel, C, Espigado, I, González-Vicent, M, Suarez-Lledó, M, García-Cadenas, I, Martino, R, Cedillo, A, Rovira, M, de la Cámara, R, Navarro, D, Solano, C. Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC). Mediterranean Journal of Hematology and Infectious Diseases. 2024; 16(1)DOI:10.4084/MJHID.2024.065. PMID:39258183. IF:1.500(Q3/8D).

24/06/2024 Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies

Fox, ML, García-Cadenas, I, Navarro, V, Martínez, AP, Kara, M, Bazán, IS, Coll, CF, Bailén, R, Bento, L, Parody, R, Esquirol, A, Orti, G, Mussetti, A, Salamero, O, Martino, R, González, AP, Barba, P, Kwon, M, Solano, C, Bosch, F, Valcárcel, D. Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies. BONE MARROW TRANSPLANTATION. 2024; 59(10)DOI:10.1038/s41409-024-02322-2. PMID:38914883. IF:5.200(Q1/1D).

19/06/2024 Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy

Pinana, JL, Vazquez, L, Heras, I, Aiello, TF, López-Corral, L, Arroyo, I, Soler-Espejo, E, García-Cadenas, I, Garcia-Gutierrez, V, Aroca, C, Chorao, P, Olave, MT, Lopez-Jimenez, J, Gómez, MA, Arellano, E, Cuesta-Casas, M, Avendano-Pita, A, González-Santillana, C, Hernández-Rivas, JA, Roldán-Perez, A, Mico-Cerdá, M, Guerreiro, M, Morell, J, Rodriguez-Galvez, P, Labrador, J, Campos, D, Cedillo, A, Vidal, CG, Martino, R, Solano, C. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy. Frontiers in Oncology. 2024; 14DOI:10.3389/fonc.2024.1389345. PMID:39015498. IF:3.300(Q2/4D).

01/05/2024 Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022.

Aerts R, Mehra V, Groll AH, Martino R, Lagrou K, Robin C, Perruccio K, Blijlevens N, Nucci M, Slavin M, Bretagne S, Cordonnier C. Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022.. LANCET INFECTIOUS DISEASES. 2024; 24(5)DOI:10.1016/S1473-3099(23)00495-4. PMID:38134949. IF:31.000(Q1/1D).

01/05/2024 Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Drozd-Sokolowska, J, Gras, L, Koster, L, Martino, R, Salas, MQ, Salmenniemi, U, Zudaire, T, Yañez, L, Bellido, M, Collin, M, Kaufmann, M, Kozlowski, P, Poiré, X, Ferra, C, Sampol, A, Wilson, KMO, Cairoli, A, Gedde-Dahl, T, Deconinck, E, Mirabile, M, Suarez, F, Raj, K, van Gelder, M, Yakoub-Agha, I, Tournilhac, O, Mclornan, DP. Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. HAEMATOLOGICA. 2024; 109(5)DOI:10.3324/haematol.2023.284359. PMID:38205539. IF:10.100(Q1/2D).

01/12/2023 Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study

Bastos-Oreiro M., Gutierrez A., Iacoboni G., López Corral L., Reguera J.L., Abrisqueta P., Delgado J., Terol M.J., Hernani R., Martínez N., Ortíz V., Bailen R., Gomez-Centurión I., Caballero A., Sanz J., Guerra Domínguez L., Luzardo H., Mussetti A., Jiménez-Ubieto A., Sancho J.M., Sureda A., Pérez A., Barba P., Kwon M., Martín García-Sancho A.. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study. Transplantation And Cellular Therapy. 2023; 29(12)DOI:10.1016/j.jtct.2023.08.026. PMID:37659694. IF:3.600(Q1/3D).

01/12/2023 Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients

Arqueros, C, Salazar, J, Gallardo, A, Andrés, M, Tibau, A, Bell, OL, Artigas, A, Lasa, A, Cajal, T, Lerma, E, Barnadas, A. Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients. Biomedicines. 2023; 11(12)DOI:10.3390/biomedicines11123231. PMID:38137452. IF:3.900(Q1/3D).

16/11/2023 Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience

Esquirol, A, Cadenas, IG, Novelli, S, Garrido, A, Caballero, AC, Oñate, G, Lopez, J, Redondo, S, Argüello, M, Saavedra, S, Moreno, C, Briones, J, Sierra, J, Martino, R. Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience. ANNALS OF HEMATOLOGY. 2023; 103(1)DOI:10.1007/s00277-023-05530-w. PMID:37971549. IF:3.000(Q2/4D).